Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)Product type:GuidanceProgramme:NICE guidelinePublished: 27 November 2024
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: 15 January 2025
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 January 2025
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 24 April 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital support for children and young people with eating disorders:early value assessmentStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC